BG-89894

DRUG2 trials

Sponsors

BeOne Medicines

Conditions

Advanced Solid TumorAdvanced or Metastatic MTAP-deleted Solid Tumors

Phase 1

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Active, not recruitingNCT06568614

BeOne MedicinesAdvanced or Metastatic MTAP-deleted Solid Tumors

Start: 2024-10-12End: 2026-04-30Updated: 2026-03-27

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

RecruitingNCT06589596

BeOne MedicinesAdvanced Solid Tumor

Start: 2024-10-11End: 2029-01-01Target: 244Updated: 2026-03-19

Related Papers

Abstract CT193: Trial in progress: A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency

Cancer Research2025-04-251 citations